Company History

March 2014 Redx Pharma and Pierre Fabre Laboratories agree major collaboration in cancer research.
November 2013 Redx Pharma named Bionow Company of the Year and one of its scientists, Dr Ralph Kirk, is named Promising Technologist of the Year.
November 2013 Redx Pharma agrees pioneering MRSA deal with NHS Royal Liverpool and Broadgreen University Hospitals Trust to work together on new drugs to combat the growing threat of anti-biotic resistance.
October 2013 Redx Pharma CEO acknowledged as the Business Leader of the Year in the annual Liverpool Post Leaders Awards.
June 2013 Redx Pharma named Knowledge Business of the Year at the Liverpool Post Regional Business Awards.
April 2013 Redx Anti-Infectives launches in Liverpool/Alderley Edge.
October 2012 Redx Pharma awarded £4.7M grant for new subsidiary Redx Anti-Infectives.
October 2012 Redx Pharma nominated for Young Company of the Year at the Growing Business Awards.
October 2012 Redx Pharma named North West's most innovative at the annual Institute of Directors Awards.
September 2012 Redx Pharma announces a licence agreement that will allow Dishman Pharmaceuticals & Chemicals to use process technology patented by the Liverpool-based firm.
April 2012 Redx is named Northwest Newcomer of the Year at the North West Business Masters.
April 2012 Redx Oncology launches in Liverpool.
November 2011 Redx receives the award for Start­‐up Company of the Year at the annual BioNow Awards.
October 2011 Redx secures £5.9m grant from Regional Growth Fund to support the launch of Redx Oncology.
June 2011 Redx wins the Liverpool Daily Post Regional Business Award for Knowledge Business of the Year.
January 2011 Redx achieves first proof of concept in anti-infective programme, second proof of concept for Redox Switch technology.
December 2010 Redx's September fundraising named as New Technology Deal of the Year in the Insider North West Dealmakers Awards 2010.
November 2010 Ahead of schedule and below budget Redx team moves into bigger lab facilities within MerseyBio; four additional staff recruited.
September 2010 BPL becomes Redx Pharma Ltd (Redx) with £2.25m investment package to develop Redox Switch technology in four initial lead programmes: cardiovascular, influenza, antibiotics and neuropathic pain. New shareholders include lifesciences specialist Jon Moulton, YFM and private investors. Investment underpins strategy to identify and develop additional families of patented drug candidates to clinical readiness, prior to out-licensing to development and commercialization partners.
September 2009 Completion of first in-vivo PoC for Redox Switch in cardiovascular programme. First demonstration that Redox Switch methodology can produce effective drugs in pre-clinical testing.
December 2008 MSIF/AFM, NWDA and private investments plus R&D grants reach funding total of £550,000.
May 2008 Chemistry PoC completed for first Redox Switch application. Positive lab results obtained in-vitro in cardiovascular programme, triggering lab expansion.
August 2007 BPL commenced operations within Liverpool University's MerseyBio incubator facility. NWDA/MSIF funding of £185k backs Redox Switch proof of concept studies (PoC) in chemistry and laboratory testing.
November 2005 Redx Pharma forerunner Bradford Pharma Ltd (BPL) established by Peter Jackson, Derek Lindsay and Norman Molyneux (Acceleris) to develop potential new active pharmaceutical compounds, using patents licensed from Avecia Pharmaceuticals. Novel chemistry modifies existing cardiovascular drugs to enable improved "next generation" therapies.